Drug
Bomedemstat
Bomedemstat: highest development phase Phase 3, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bomedemstat NCT06351631 | Phase 3 | Thrombocythemia, Essential |
| Bomedemstat NCT05191797 | Phase 1/2 | Extensive Stage Lung Small Cell Carcinoma |
Latest
Follow Bomedemstat on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.